The Egyptian Journal of Bronchology

Table 1 Effect of tocilizumab administration on symptoms

From: Safety and efficacy of tocilizumab in critically ill patients with COVID-19: an observational study

	Dyspnea			Total	P value*
	3.00		4.00	Total	P value*
Dyspnea (MMRC)	3.00	0	2	2	0.29 NS
Dyspnea (MMRC)	4.00	6	42	48
Total	6		44	50
	Cough after			Total	P value*
	No		Yes	Total	P value*
Cough before	No	2	7	9	1.00 NS
Cough before	Yes	6	35	41
Total	8		42	50
	Expectoration after			Total	P value*
	No		Yes	Total	P value*
Expectoration before	No	34	12	46	< 0.001 HS
Expectoration before	Yes	0	4	4
Total	34		16	50
	Bony aches after			Total	P value*
	No		Yes	Total	P value*
Bony aches before	No	2	3	5	0.01 HS
Bony aches before	Yes	14	31	45
Total	16		34	50
	Fatigue after			Total	P value*
	No		Yes	Total	P value*
Fatigue before	No	2	3	5	0.01 HS
Fatigue before	Yes	15	30	45
Total	17		33	50
	Loss of taste after			Total	P value*
	No		Yes	Total	P value*
Loss of taste before	No	41	4	45	0.13 NS
Loss of taste before	Yes	0	5	5
Total	41		9	50
	Anosmia after			Total	P value*
	No		Yes	Total	P value*
Anosmia before	No	40	4	44	0.13 NS
Anosmia before	Yes	0	6	6
Total	40		10	50
	Sore throat after			Total	P value*
	No		Yes	Total	P value*
Sore throat before	No	23	7	30	0.80 NS
Sore throat before	Yes	9	11	20
Total	32		18	50
	Fever after			Total	P value*
	No		Yes	Total	P value*
Fever before	No	12	6	18	0.01 HS
Fever before	Yes	21	11	32
Total	33		17	50

^*McNemar’s test

Back to article page